Neurocrine (NBIX) Insider Gift of 1,470 Shares Reported

Rhea-AI Filing Summary

Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences, reported a non-market transfer of common stock on 09/03/2025. The filing shows 1,470 shares were disposed of as a gift/charitable contribution with no cash received, and 13,703 shares remained beneficially owned after the transaction. The Form 4 was signed by an attorney-in-fact on 09/04/2025 and lists the transaction code as G(1), indicating a gift. No derivative securities were reported.

Insights

Securities Compliance Analyst

TL;DR: Routine insider gift disclosure showing a small reduction in direct holdings; no market sale or change to derivative positions.

The Form 4 documents a non-market transfer of 1,470 common shares from Onyia Jude effective 09/03/2025, reported under transaction code G(1) which denotes a gift. The filing reports 13,703 shares beneficially owned after the transaction and indicates no price because no value was received. From a compliance standpoint this is a standard Section 16 disclosure of a charitable gift and appears to follow required timing and signature conventions.

Corporate Governance Specialist

TL;DR: Insider reduced holdings via gift; disclosure is standard and not indicative of trading activity.

The report identifies the reporting person as the Chief Scientific Officer and shows a direct disposition of shares via gift, not a sale. There are no changes to derivative positions and no proceeds were reported. This type of Form 4 typically has limited governance or financial implications beyond ownership disclosure. The timely filing and attorney-in-fact signature meet procedural expectations.

Insider Trade Summary

1,470 shares gifted

Mixed 1 txn

Insider Onyia Jude

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	1,470	$0.00	--

Holdings After Transaction: Common Stock — 13,703 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Onyia Jude

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		G(1)		1,470	D	$0	13,703	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction represents a gift/charitable contribution effective September 3, 2025. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.